Last reviewed · How we verify
APVAC2 vaccine plus Poly-ICLC and GM-CSF
APVAC2 vaccine plus Poly-ICLC and GM-CSF is a Cancer immunotherapy Small molecule drug developed by Immatics Biotechnologies GmbH. It is currently in Phase 1 development for Non-small cell lung cancer. Also known as: Actively Personalized Vaccine, Hiltonol, Leukine.
APVAC2 vaccine plus Poly-ICLC and GM-CSF is a cancer immunotherapy that targets tumor cells by stimulating the immune system through activation of dendritic cells and subsequent activation of T cells.
APVAC2 vaccine plus Poly-ICLC and GM-CSF is a cancer immunotherapy that targets tumor cells by stimulating the immune system through activation of dendritic cells and subsequent activation of T cells. Used for Non-small cell lung cancer.
At a glance
| Generic name | APVAC2 vaccine plus Poly-ICLC and GM-CSF |
|---|---|
| Also known as | Actively Personalized Vaccine, Hiltonol, Leukine |
| Sponsor | Immatics Biotechnologies GmbH |
| Drug class | Cancer immunotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
APVAC2 is a vaccine that targets tumor cells, while Poly-ICLC is a Toll-like receptor 3 agonist that stimulates the immune system, and GM-CSF is a cytokine that promotes the activation of dendritic cells and T cells.
Approved indications
- Non-small cell lung cancer
Common side effects
- Injection site reaction
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APVAC2 vaccine plus Poly-ICLC and GM-CSF CI brief — competitive landscape report
- APVAC2 vaccine plus Poly-ICLC and GM-CSF updates RSS · CI watch RSS
- Immatics Biotechnologies GmbH portfolio CI
Frequently asked questions about APVAC2 vaccine plus Poly-ICLC and GM-CSF
What is APVAC2 vaccine plus Poly-ICLC and GM-CSF?
How does APVAC2 vaccine plus Poly-ICLC and GM-CSF work?
What is APVAC2 vaccine plus Poly-ICLC and GM-CSF used for?
Who makes APVAC2 vaccine plus Poly-ICLC and GM-CSF?
Is APVAC2 vaccine plus Poly-ICLC and GM-CSF also known as anything else?
What drug class is APVAC2 vaccine plus Poly-ICLC and GM-CSF in?
What development phase is APVAC2 vaccine plus Poly-ICLC and GM-CSF in?
What are the side effects of APVAC2 vaccine plus Poly-ICLC and GM-CSF?
Related
- Drug class: All Cancer immunotherapy drugs
- Manufacturer: Immatics Biotechnologies GmbH — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Also known as: Actively Personalized Vaccine, Hiltonol, Leukine
- Compare: APVAC2 vaccine plus Poly-ICLC and GM-CSF vs similar drugs
- Pricing: APVAC2 vaccine plus Poly-ICLC and GM-CSF cost, discount & access